This phase II trial studies how well afatinib dimaleate works in treating patients with
urothelial cancer that cannot be removed surgically and has grown after treatment with
standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the
epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors,
which may slow the growth of cancer cells or cause some of the cells to die.